Results 151 to 160 of about 83,360 (210)

Increased expression of inflammasome signaling genes and proteins in selective brain regions in the intermediate stage of Alzheimer's disease

open access: yesBrain Pathology, EarlyView.
Neuritic plaques increase in the intermediate stage of Alzheimer's neuropathological change. The intermediate stage of Alzheimer's disease was investigated by transcriptomics and immunohistochemistry. This revealed that inflammasome sensors NLRP1, NLRP3, and AIM2 oligomerize with ASC speck to form the inflammasome complex and initiate the downstream ...
Juan Pablo de Rivero Vaccari   +10 more
wiley   +1 more source

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

open access: yesBrain Pathology, EarlyView.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira   +19 more
wiley   +1 more source

New perspectives on VEGF signalling in Alzheimer's disease

open access: yesBrain Pathology, EarlyView.
Emery et al. bring together findings from recent multi‐omic studies, including single‐cell mRNA analysis of human post‐mortem brain tissue, and proteomic analysis of matched CSF and blood samples in large clinical studies. The authors present evidence of the involvement of altered VEGF signalling in vascular and immune dysfunction and neurodegeneration
Cherelle E. G. Emery   +2 more
wiley   +1 more source

Human brain matters: Navigating the neuropathology of COVID‐19

open access: yesBrain Pathology, EarlyView.
Severe COVID‐19 is associated with vascular dysregulation and chronic neuroinflammation, leading to axonal injury and neurodegeneration. In long COVID or PASC, persistent alterations in neuroimaging and biofluid biomarkers reflect ongoing neuronal damage and neuroinflammation, contributing to long‐term neurological symptoms including fatigue, cognitive
Juliana M. Nieuwland   +4 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy